24 healthy male and female volunteers, age 18-35 yrs., smokers (at least 10 cigarettes/day since 2 years) 24 healthy male and female volunteers, age 18-35 yrs., nonsmokers (since at least 2 years).
Conditions
Interventions
Product Name: L-NMMA
Pharmaceutical Form: Intravenous infusion
INN or Proposed INN: NG-monomethyl-L-arginine (L-NMMA)
Concentration unit: mg/kg milligram(s)/kilogram
Concentration type: equal
Concent
Sponsors
Department of Clinical Pharmacology
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Inclusion criteria - Men and Women aged between 18 and 35 years, nonsmokers - Body mass index between 15th and 85th percentile (Must et al., 1991) - Normal findings in the medical history and physical examination unless the investigator considers an abnormality to be clinically irrelevant - Normal laboratory values unless the investigator considers an abnormality to be clinically irrelevant - Normal ophthalmic findings, ametropy =65 years) no F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: Exclusion criteria Any of the following will exclude a healthy subject from the study: - Regular use of medication, abuse of alcoholic beverages, participation in a clinical trial in the 3 weeks preceding the study - Treatment in the previous 3 weeks with any drug - Symptoms of a clinically relevant illness in the 3 weeks before the first study day - Blood donation during the previous 3 weeks - Ametropy > 3 Dpt
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: To investigate the effect of L-NMMA on retinal and choroidal blood flow in smokers compared to non-smokers.;Secondary Objective: ;Primary end point(s): | — |
Countries
Austria
Outcome results
None listed